If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Bermuda thanks very much for that - 'recognition' by CEPI for Covidity is indeed a 'big deal' and just one other Gen 2 project is mentioned. It seems to me there's a tremendous amount of groundwork going on and whatever is said about CH, a lot of this has been brought through under his 'stewardship'.
For those looking in casually, I take the liberty of posting the script again :-
"Instead of using the spike protein of the COVID-19 virus, which is prone to mutations, as the key target for coronavirus vaccines, researchers are assessing other parts of the virus that are known to be more stable. For example, scientists at the University of Nottingham in the UK are working alongside pharmaceutical company Scancell and Nottingham Trent University to test its COVID-19 vaccine candidate, SN14, which targets both the spike protein as well as the nucleocapsid, or N-protein. By targeting this additional viral structure, which is far less likely to mutate, the vaccine if found safe and effective could work to protect people against COVID-19 irrespective of any mutations to the spike protein and, in theory, could work across other coronaviruses." https://cepi.net/news_cepi/going-universal-the-search-for-an-all-in-one-coronavirus-vaccine/
Crumbs - at the moment I'm not taking this as anything other than recognition of Scancell's vaccine by CEPI and as you've identified, it's a big deal. If anyone isn't sure worth checking out the names and institutions involved with CEPI. The following is nearly a year old but gives an idea of the the level CEPI are operating at. It's really quite something that they've singled out Scancell/UoN:-
'So today leaders came together at a virtual event, co-hosted by the World Health Organization, the President of France, the President of the European Commission, and the Bill & Melinda Gates Foundation. The event was joined by the UN Secretary General, the AU Commission Chairperson, the G20 President, heads of state of France, South Africa, Germany, Vietnam, Costa Rica, Italy, Rwanda, Norway, Spain, Malaysia and the UK (represented by the First Secretary of State).
Health leaders from the Coalition for Epidemic Preparedness Innovations (CEPI), GAVI-the Vaccine Alliance, the Global Fund, UNITAID, the Wellcome Trust, the International Red Cross and Red Crescent Movement (IFRC), the International Federation of Pharmaceutical Manufacturers (IFPMA), the Developing Countries Vaccine Manufacturers’ Network (DCVMN), and the International Generic and Biosimilar Medicines Association (IGBA) committed to come together, guided by a common vision of a planet protected from human suffering and the devastating social and economic consequences of COVID-19, to launch this groundbreaking collaboration. They are joined by two Special Envoys: Ngozi Okonjo-Iweala, Gavi Board Chair and Sir Andrew Witty, former CEO of GlaxoSmithKline.'
https://www.who.int/news/item/24-04-2020-global-leaders-unite-to-ensure-everyone-everywhere-can-access-new-vaccines-tests-and-treatments-for-covid-19
Sorry the inovio vax that they are working with is not a covid one!... they do have one though ... a bit of a troubled one
BTW CEPI are not new to DNA covid vaxs they already work with our old mates inovio ....
https://cepi.net/news_cepi/cepi-partner-inovio-launches-lassa-vaccine-phase-i-trial-in-west-africa/
If there is indeed something brewing with CEPI it could open up all kinds of possibilities with where Covidity could possibly be trialled etc... anyways, for now, nice to have the recognition and well-done boom for your tweeting work too... notice scancell retweeted both yours and then official CEPI tweet... but theirs is already getting the inovio investor treatment lol
Totally agree there.... we are on or at least getting on the right radars and the virus is doing its bit too
Could be crumbs. We have to wait and see.
One thing is sure, having a paragraph in a CEPI blog (they have an eye on Scancell) is better than any newspaper publicity.
Ray, I think the notts delivery will come in house too making ImmunoBody a completely new package ... fits with what Cliff said in the presentation
Always best to go after more than just the spike :)
Thanks for this Bermuda.
This bit is also relevant to Scancell's Immunobody and Avidimab platforms
"Second, we will fund new and innovative platform technologies with the potential to accelerate the development and manufacture of vaccines against previously unknown pathogens (eg: within 16 weeks from identification of antigen to product release for clinical trials)—”just in time”."
I reckon 16 weeks from antigen recognition to clinical trial is possible for Scancell's platforms once the delivery is finalised.
IMO the delivery will be the same for all Immunobody/Avidimab vaccines i.e. attach to soft muscle cells and APCs.
C7
What has changed?? Nothing, except CH never told us to pile in this week for news, well he was never going to was he??
quite.. what has changed is more sellers than buyers hasibos is prime example the shares he is selling are in a company that is just in the same position as the ones he bought into just he made a profit .... so no need for all the other guffins ... cardboad labs indeed pfft
Chester, you're right about that intriguing slide... though as far as we know via RNS SN14 is chosen and the one undergoing manufacture... obviously lots going on trying to find our niche in the current vaccine sphere... Cliff mentions Covidity being a 'booster'....
I reckon a lot is going to be down to who is showing an interest and what their interest is...
Thanks for that Bermuda, an interesting article.
Hoping for a blue day tomorrow, as many of us who have taken some profit, like me see a better re entry point. We saw on Friday support at 23 crumble to 21.5 which it has again today but hoping as on Friday we return to 22.72 in a very short time which allowed me to close a trade £18 up, after looking at a £400 loss which would have wiped out my weeks profit, so grateful for that.
Looking to get my holding back up from 220k so will be waiting in the morning to press the buy button.
What has changed?? Nothing, except CH never told us to pile in this week for news, well he was never going to was he??
Bring on tomorrow a volatile market which I am sure is not lost on others works in our favour too, expected todays drop, hence why I closed my trade on Friday, hoping tomorrow for a blue day, we are 20% down in just a few days but that little mention on Sky means we are on the radar and I can think of a few Big Pharmas where that is the case too, and I believe that will come as news in the not too distant future.
Best of luck all, as positive as ever, but understand the fall in recent days too. Goodnight.
Hi Bermudashorts
In that article they are specifying SN14 but during Cliffs presentation last week it stated on one of the slides, Lead Candidate (SN15 / SCOV1). Just pointing that out.
Chester.
'Both Norway and Germany are long-term partners and two of the biggest investors in CEPI’s work. Norway was one of CEPI’s founding members when the organisation launched, in the wake of the 2014-16 Ebola epidemic, as the result of a consensus that a coordinated, international, and intergovernmental plan was needed to develop and deploy new vaccines to prevent future epidemics. The Government of Germany also provided significant financial contributions to advance CEPI’s mission in 2017 through the German Federal Minister of Education and Research (Bundesministerium für Bildung und Forschung; BMBF) and again in 2020 to support the establishment of CEPI’s COVID-19 vaccine portfolio.
The new funding will support CEPI’s goal of raising $1 billion in 2021 to carry out critical R&D to future-proof vaccines against emerging variants, maximise the available supply of vaccines, and fill in current clinical research and development gaps to optimise the use of the vaccines we have.'
of course 'future proof' is no guarantee of past share price performance :)
Brilliant ....Not just on the next-gen vax map but a recognised landmark...
'CEPI is an innovative global partnership between public, private, philanthropic, and civil society organisations launched in Davos in 2017 to develop vaccines to stop future epidemics.
Our mission is to accelerate the development of vaccines against emerging infectious diseases and enable equitable access to these vaccines for people during outbreaks.'
'Many organisations operate within the end-to-end space of vaccine funding and R&D implementation. However, a number of critical gaps have been identified, which CEPI was designed to fill.
First, CEPI will advance vaccines against known threats through proof-of-concept and safety testing in humans and will establish investigational vaccine stockpiles before epidemics begin—”just in case”.
Second, we will fund new and innovative platform technologies with the potential to accelerate the development and manufacture of vaccines against previously unknown pathogens (eg: within 16 weeks from identification of antigen to product release for clinical trials)—”just in time”.
Third, CEPI will support and coordinate activities to improve our collective response to epidemics, strengthen capacity in countries at risk, and advance the regulatory science that governs product development.'
Great coverage here from CEPI for Scancell
'Instead of using the spike protein of the COVID-19 virus, which is prone to mutations, as the key target for coronavirus vaccines, researchers are assessing other parts of the virus that are known to be more stable.
For example, scientists at the University of Nottingham in the UK are working alongside pharmaceutical company Scancell and Nottingham Trent University to test its COVID-19 vaccine candidate, SN14, which targets both the spike protein as well as the nucleocapsid, or N-protein. By targeting this additional viral structure, which is far less likely to mutate, the vaccine if found safe and effective could work to protect people against COVID-19 irrespective of any mutations to the spike protein and, in theory, could work across other coronaviruses.'
https://cepi.net/news_cepi/going-universal-the-search-for-an-all-in-one-coronavirus-vaccine/